Nemaura Medical (NSDQ:NMRD) plans to expand into new manufacturing facilities in preparation for the commercial launch of its non-invasive glucose monitoring system.
The company expects to win CE Mark approval for its sugarBeat system in the coming months and also hopes to launch additional trials in the U.S. to support a regulatory bid with the FDA.
Get the full story at our sister site, Drug Delivery Business News.
The post Preparing for commercial launch, Nemaura boosts manufacturing capabilities appeared first on MassDevice.
from MassDevice http://ift.tt/2FhrVIs
Cap comentari:
Publica un comentari a l'entrada